Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of GC12-132 in r/r AML
NCT06110208Phase 1Terminated
- Start
- Oct 2023
- Primary completion
- Jul 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CLL1/CD38 dual CAR-T in acute myeloid leukemia (AML). Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events at 48 weeks. Started Oct 2023; status: terminated.
02
Drugs
CLL1/CD38 dual CAR-T
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06110208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06110208.